High-Dose (80 Gy) Intensity-Modulated Radiation Therapy with Daily Image-Guidance as Primary treatment for Localized Prostate Cancer

Abstract

GI toxicity rates after IMRT with daily image-guidance were excellent. GU toxicity rates were acceptable and strongly related to PGUM.

Dose-escalated simultaneous integrated-boost treatment of prostate cancer patients via helical tomotherapy

“…The assessment of acute side effects showed low therapy related GU and GI toxicity in spite of modest dose escalation up to 76 Gy with 2.17 Gy per fraction and a permitted dose of 76 Gy to the anterior rectal wall. This is in line with other studies on dose escalation using IMRT [2,9,16,36] or hypofractionated treatment of prostate cancer [19,23,26,27,33] and studies combining hypofractionation and dose escalation applying a SIB [5,12,14], although the dose to the anterior rectal wall was limited to lower doses in several of these studies as compared to our protocol, either by excluding the rectal overlap from the boost volume or restricting the allowed doses to the overlap regions at lower dose levels.…”

Comparison of preoperative short-course radiotherapy and long-course radiochemotherapy for locally advanced rectal cancer

“…These data support the use of SC-RT in the elderly patient population. Similar to experiences made in other pelvic cancers, advanced radiotherapy technologies may reduce acute side effects and, therefore, improve results of LC-RCHT in these fragile patients [19,20,21,22]. Some limitations of our study need to be discussed.…”

Comparison of seed brachytherapy or external beam radiotherapy (70 Gy or 74 Gy) in 919 low-risk prostate cancer patients

“…By the integration of more advanced imaging and treatment techniques such as imageguided radiotherapy or intensity-modulated radiotherapy dose is going to be increased further to achieve even better results. However by increasing dose, the risk to develop more severe acute and late toxicity also rises [1,8,9,13,24]. A reasonable effort, therefore, is to detect the dose level required within EBRT when treating low-risk prostate cancer patients in order to achieve similar excellent tumor control rates as obtained by seed BT, while not exceeding local dose too far.…”